XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jul. 22, 2024
May 25, 2023
Jul. 30, 2022
Jun. 01, 2021
May 31, 2021
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Deferred revenue           $ 680   $ 555
Deferred revenue recognized           200 $ 600  
Remaining performance obligation           1,800    
Grant period (in years)         5 years      
Research and development arrangement with federal government, total budget         $ 9,300      
Research and development arrangement with federal government, funding for subawards         $ 5,500      
Approved funding, first year       $ 800        
Approved funding for subawards, first year       $ 400        
Approval for funding, year two     $ 2,600          
Approval for funding, subawards, year two     $ 1,600          
Approval for funding, year three   $ 3,000            
Approval for funding subawards, year three   $ 1,500            
Approval for funding, year four $ 1,700              
Approval for funding subawards, year four $ 1,000              
Funding received for costs incurred           100 $ 400  
Prepaid expenses and other current assets           2,201   $ 2,352
Additional Funding Agreement Terms                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Compensation earned           3,900    
Prepaid expenses and other current assets           100    
Variety of Health Care Organizations | UNITED STATES | Accounts Receivable | Customer Concentration Risk                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Accounts receivable, with the exception of due           $ 100